Real-World data reveals how kidney cancer drug performs

NCT ID NCT07354282

Completed Disease control Sponsor: Spanish Oncology Genito-Urinary Group Source: ClinicalTrials.gov ↗

Summary

This study looked back at medical records to see how well the drug tivozanib worked for 200 people with advanced kidney cancer that had spread. Researchers wanted to understand how long patients lived without their cancer getting worse and how long they lived overall after starting this treatment. The goal was to gather real-world evidence on controlling this serious disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fundacion Jimenez Diaz

Madrid, Madrid, Spain
Hospital Gregorio Marañon

Madrid, Madrid, Spain
Hospital Lucus Augusti

Lugo, Galicia, Spain
Hospital Parc Tauli

Sabadell, Catalonia, Spain
Hospital Puerta de Hierro

Majadahonda, Madrid, Spain
Hospital Reina Sofia

Córdoba, Andalusia, Spain
Hospital Severo Ochoa

Leganés, Madrid, Spain
Hospital Vall de Hebron

Barcelona, Catalonia, Spain
Hospital Virgen de la Victoria

Málaga, Andalusia, Spain
Hospital Virgen del Rocio

Seville, Andalusia, Spain
Hospital de Burgos

Burgos, Castille and León, Spain
Hospital de Leon

León, Castille and León, Spain
Institut Català d'Oncologia (ICO) de L'Hospitalet de Llobregat

L'Hospitalet de Llobregat, Catalonia, Spain
Instituto Valenciano de Oncologia (IVO)

Valencia, Valencia, Spain

Conditions

Explore the condition pages connected to this study.

RENAL CELL CANCER METASTATIC